{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:15:43Z","timestamp":1790745343861,"version":"4.1.0"},"reference-count":35,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Unlike B-cell acute lymphoblastic leukemia\/lymphoma (ALL\/LBL), there have been few therapeutic advances in T-cell ALL (T-ALL)\/LBL, an aggressive ALL\/LBL subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To perform a focused tissue array study to elucidate tumor markers of therapeutic potential in T-ALL\/LBL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Using immunohistochemistry, we evaluated expression of leukemic antigens of interest, specifically CC-chemokine receptor 4 (CCR4), among others, on available remnant diagnostic material, including tumor tissue slides obtained from formalin-fixed, paraffin-embedded preserved tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Our analysis identified, for the first time, expression of CCR4 in T-ALL\/LBL in 11 of 27 cases (40.7%) and confirmed common expression of BCL2, CD38, and CD47, as reported previously. We also identified the expression of CD123 in 4 of 26 cases (15.4%), whereas BCL6 and PDL1 were expressed in a small number of T-ALL\/LBL cases. The potential novel target CCR4 was significantly more common in the Pre\/Pro-T immunophenotypic subtype, 6 of 9 (66.7%, P = .01). No additional differences in clinical and epidemiologic variables were noted among positive or negative CCR4 cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>These findings support preclinical and clinical testing of therapies targeting CCR4, CD47, BCL2, CD38, and CD123 in T-ALL\/LBL, and may help guide the development of targeted clinical trials in T-ALL\/LBL, a rare disease in urgent need of novel therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2022-0482-oa","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T08:59:02Z","timestamp":1690793942000},"page":"471-475","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia\/Lymphoma: A Mayo Clinic Clinical and Pathologic Study"],"prefix":"10.5858","volume":"148","author":[{"given":"Sharad","family":"Khurana","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology, University of Arizona Cancer Center, Tucson (Khurana)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Heckman","sequence":"additional","affiliation":[{"name":"the Departments of Biomedical Statistics and Informatics (Heckman, Cochuyt) and Laboratory Medicine and Pathology (Jiang), and the Division of Hematology and Medical Oncology (Foran), Mayo Clinic Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E.","family":"Craig","sequence":"additional","affiliation":[{"name":"the Divisions of Hematopathology (Craig) and Hematology and Medical Oncology (Sproat), Mayo Clinic Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Cochuyt","sequence":"additional","affiliation":[{"name":"the Departments of Biomedical Statistics and Informatics (Heckman, Cochuyt) and Laboratory Medicine and Pathology (Jiang), and the Division of Hematology and Medical Oncology (Foran), Mayo Clinic Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[{"name":"the Divisions of Laboratory Genetics (Greipp) and Hematology (Litzow), Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid Abdel","family":"Rahman","sequence":"additional","affiliation":[{"name":"the Division of Hematology and Medical Oncology, Sanford Roger Maris Cancer Center, Fargo, North Dakota (Rahman)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Z.","family":"Sproat","sequence":"additional","affiliation":[{"name":"the Divisions of Hematopathology (Craig) and Hematology and Medical Oncology (Sproat), Mayo Clinic Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"the Divisions of Laboratory Genetics (Greipp) and Hematology (Litzow), Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"the Departments of Biomedical Statistics and Informatics (Heckman, Cochuyt) and Laboratory Medicine and Pathology (Jiang), and the Division of Hematology and Medical Oncology (Foran), Mayo Clinic Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyan (Jennifer)","family":"Jiang","sequence":"additional","affiliation":[{"name":"the Departments of Biomedical Statistics and Informatics (Heckman, Cochuyt) and Laboratory Medicine and Pathology (Jiang), and the Division of Hematology and Medical Oncology (Foran), Mayo Clinic Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2024032423502141800_i1543-2165-148-4-471-b01","doi-asserted-by":"crossref","unstructured":"Ma\n              H,\n            \n            \n              Sun\n              H,\n            \n            \n              Sun\n              X.\n            \n          \n          Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. \nSci Rep. \n2014;\n4:4227. \ndoi:10.1038\/srep04227","DOI":"10.1038\/srep04227"},{"key":"2024032423502141800_i1543-2165-148-4-471-b02","doi-asserted-by":"crossref","unstructured":"Stock\n              W,\n            \n            \n              Luger\n              SM,\n            \n            \n              Advani\n              AS,\n            \n            et al. \n\n          A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. \nBlood. \n2019;\n133(14):1548\u20131559. \ndoi:10.1182\/blood-2018-10-881961. Erratum in Blood. 2019;134(13):1111. doi:10.1182\/blood.2019002613","DOI":"10.1182\/blood.2019002613"},{"key":"2024032423502141800_i1543-2165-148-4-471-b03","doi-asserted-by":"crossref","unstructured":"Pulte\n              D,\n            \n            \n              Jansen\n              L,\n            \n            \n              Gondos\n              A,\n            \n            et al. \n\n          Survival of adults with acute lymphoblastic leukemia in Germany and the United States. \nPLoS One. \n2014;\n9(1):e85554. \ndoi:10.1371\/journal.pone.0085554","DOI":"10.1371\/journal.pone.0085554"},{"key":"2024032423502141800_i1543-2165-148-4-471-b04","doi-asserted-by":"crossref","unstructured":"Sive\n              JI,\n            \n            \n              Buck\n              G,\n            \n            \n              Fielding\n              A,\n            \n            et al. \n\n          Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. \nBr J Haematol. \n2012;\n157(4):463\u2013471. \ndoi:10.1111\/j.1365-2141.2012.09095.x","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"2024032423502141800_i1543-2165-148-4-471-b05","doi-asserted-by":"crossref","unstructured":"Fielding\n              AK,\n            \n            \n              Richards\n              SM,\n            \n            \n              Chopra\n              R,\n            \n            et al. \n\n          Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. \nBlood. \n2007;\n109(3):944\u2013950. \ndoi:10.1182\/blood-2006-05-018192","DOI":"10.1182\/blood-2006-05-018192"},{"key":"2024032423502141800_i1543-2165-148-4-471-b06","doi-asserted-by":"crossref","unstructured":"Hefazi\n              M,\n            \n            \n              Litzow\n              MR.\n            \n          \n          Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. \nBlood Lymphat Cancer. \n2018;\n8:47\u201361. \ndoi:10.2147\/BLCTT.S170351","DOI":"10.2147\/BLCTT.S170351"},{"key":"2024032423502141800_i1543-2165-148-4-471-b07","doi-asserted-by":"crossref","unstructured":"Yoshie\n              O,\n            \n            \n              Matsushima\n              K.\n            \n          \n          CCR4 and its ligands: from bench to bedside. \nInt Immunol. \n2015;\n27(1):11\u201320. \ndoi:10.1093\/intimm\/dxu079","DOI":"10.1093\/intimm\/dxu079"},{"key":"2024032423502141800_i1543-2165-148-4-471-b08","doi-asserted-by":"crossref","unstructured":"Zlotnik\n              A,\n            \n            \n              Yoshie\n              O.\n            \n          \n          Chemokines: a new classification system and their role in immunity. \nImmunity. \n2000;\n12(2):121\u2013127. \ndoi:10.1016\/s1074-7613(00)80165-x","DOI":"10.1016\/S1074-7613(00)80165-X"},{"key":"2024032423502141800_i1543-2165-148-4-471-b09","doi-asserted-by":"crossref","unstructured":"Ollila\n              TA,\n            \n            \n              Sahin\n              I,\n            \n            \n              Olszewski\n              AJ.\n            \n          \n          Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. \nOnco Targets Ther. \n2019;\n12:1085\u20131094. \ndoi:10.2147\/OTT.S165615","DOI":"10.2147\/OTT.S165615"},{"key":"2024032423502141800_i1543-2165-148-4-471-b10","doi-asserted-by":"crossref","unstructured":"Campbell\n              JJ,\n            \n            \n              Haraldsen\n              G,\n            \n            \n              Pan\n              J,\n            \n            et al. \n\n          The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. \nNature. \n1999;\n400(6746):776\u2013780. \ndoi:10.1038\/23495","DOI":"10.1038\/23495"},{"key":"2024032423502141800_i1543-2165-148-4-471-b11","doi-asserted-by":"crossref","unstructured":"Narducci\n              MG,\n            \n            \n              Scala\n              E,\n            \n            \n              Bresin\n              A,\n            \n            et al. \n\n          Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV. \nBlood. \n2006;\n107(3):1108\u20131115. \ndoi:10.1182\/blood-2005-04-1492","DOI":"10.1182\/blood-2005-04-1492"},{"key":"2024032423502141800_i1543-2165-148-4-471-b12","doi-asserted-by":"crossref","unstructured":"Inngjerdingen\n              M,\n            \n            \n              Damaj\n              B,\n            \n            \n              Maghazachi\n              AA.\n            \n          \n          Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. \nJ Immunol. \n2000;\n164(8):4048\u20134054. \ndoi:10.4049\/jimmunol.164.8.4048","DOI":"10.4049\/jimmunol.164.8.4048"},{"key":"2024032423502141800_i1543-2165-148-4-471-b13","doi-asserted-by":"crossref","unstructured":"Liu\n              LY,\n            \n            \n              Jarjour\n              NN,\n            \n            \n              Busse\n              WW,\n            \n            \n              Kelly\n              EA.\n            \n          \n          Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge. \nJ Allergy Clin Immunol. \n2003;\n112(3):556\u2013562. \ndoi:10.1016\/s0091-6749(03)01798-6","DOI":"10.1016\/S0091-6749(03)00016-2"},{"key":"2024032423502141800_i1543-2165-148-4-471-b14","doi-asserted-by":"crossref","unstructured":"Clemetson\n              KJ,\n            \n            \n              Clemetson\n              JM,\n            \n            \n              Proudfoot\n              AE,\n            \n            \n              Power\n              CA,\n            \n            \n              Baggiolini\n              M,\n            \n            \n              Wells\n              TN.\n            \n          \n          Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. \nBlood. \n2000;\n96(13):4046\u20134054.","DOI":"10.1182\/blood.V96.13.4046.h8004046_4046_4054"},{"key":"2024032423502141800_i1543-2165-148-4-471-b15","doi-asserted-by":"crossref","unstructured":"Kunkel\n              EJ,\n            \n            \n              Boisvert\n              J,\n            \n            \n              Murphy\n              K,\n            \n            et al. \n\n          Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. \nAm J Pathol. \n2002;\n160(1):347\u2013355. \ndoi:10.1016\/S0002-9440(10)64378-7","DOI":"10.1016\/S0002-9440(10)64378-7"},{"key":"2024032423502141800_i1543-2165-148-4-471-b16","doi-asserted-by":"crossref","unstructured":"Andrew\n              DP,\n            \n            \n              Ruffing\n              N,\n            \n            \n              Kim\n              CH,\n            \n            et al. \n\n          C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. \nJ Immunol. \n2001;\n166(1):103\u2013111. \ndoi:10.4049\/jimmunol.166.1.103","DOI":"10.4049\/jimmunol.166.1.103"},{"key":"2024032423502141800_i1543-2165-148-4-471-b17","doi-asserted-by":"crossref","unstructured":"Yoshie\n              O,\n            \n            \n              Fujisawa\n              R,\n            \n            \n              Nakayama\n              T,\n            \n            et al. \n\n          Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. \nBlood. \n2002;\n99(5):1505\u20131511. \ndoi:10.1182\/blood.v99.5.1505","DOI":"10.1182\/blood.V99.5.1505"},{"key":"2024032423502141800_i1543-2165-148-4-471-b18","doi-asserted-by":"crossref","unstructured":"Ferenczi\n              K,\n            \n            \n              Fuhlbrigge\n              RC,\n            \n            \n              Pinkus\n              J,\n            \n            \n              Pinkus\n              GS,\n            \n            \n              Kupper\n              TS.\n            \n          \n          Increased CCR4 expression in cutaneous T cell lymphoma. \nJ Invest Dermatol. \n2002;\n119(6):1405\u20131410. \ndoi:10.1046\/j.1523-1747.2002.19610.x","DOI":"10.1046\/j.1523-1747.2002.19610.x"},{"key":"2024032423502141800_i1543-2165-148-4-471-b19","doi-asserted-by":"crossref","unstructured":"Jones\n              D,\n            \n            \n              O'Hara\n              C,\n            \n            \n              Kraus\n              MD,\n            \n            et al. \n\n          Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. \nBlood. \n2000;\n96(2):685\u2013690.","DOI":"10.1182\/blood.V96.2.685"},{"key":"2024032423502141800_i1543-2165-148-4-471-b20","doi-asserted-by":"crossref","unstructured":"Sokolowska-Wojdylo\n              M,\n            \n            \n              Wenzel\n              J,\n            \n            \n              Gaffal\n              E,\n            \n            et al. \n\n          Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. \nBr J Dermatol. \n2005;\n152(2):258\u2013264. \ndoi:10.1111\/j.1365-2133.2004.06325.x","DOI":"10.1111\/j.1365-2133.2004.06325.x"},{"key":"2024032423502141800_i1543-2165-148-4-471-b21","doi-asserted-by":"crossref","unstructured":"Yagi\n              H,\n            \n            \n              Seo\n              N,\n            \n            \n              Ohshima\n              A,\n            \n            et al. \n\n          Chemokine receptor expression in cutaneous T cell and NK\/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. \nAm J Surg Pathol. \n2006;\n30(9):1111\u20131119. \ndoi:10.1097\/01.pas.0000213267.92349.59","DOI":"10.1097\/01.pas.0000213267.92349.59"},{"key":"2024032423502141800_i1543-2165-148-4-471-b22","doi-asserted-by":"crossref","unstructured":"Ishida\n              T,\n            \n            \n              Inagaki\n              H,\n            \n            \n              Utsunomiya\n              A,\n            \n            et al. \n\n          CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. \nClin Cancer Res. \n2004;\n10(16):5494\u20135500. \ndoi:10.1158\/1078-0432.CCR-04-0371","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"2024032423502141800_i1543-2165-148-4-471-b23","doi-asserted-by":"crossref","unstructured":"Khurana\n              S,\n            \n            \n              Beltran\n              M,\n            \n            \n              Jiang\n              L,\n            \n            \n              Ayala\n              E,\n            \n            \n              Roy\n              V.\n            \n          \n          Primary cutaneous T-cell lymphoblastic lymphoma: case report and literature review. \nCase Rep Hematol. \n2019;\n2019:3540487. \ndoi:10.1155\/2019\/3540487","DOI":"10.1155\/2019\/3540487"},{"key":"2024032423502141800_i1543-2165-148-4-471-b24","doi-asserted-by":"crossref","unstructured":"Vezzoli\n              P,\n            \n            \n              Novara\n              F,\n            \n            \n              Fanoni\n              D,\n            \n            et al. \n\n          Three cases of primary cutaneous lymphoblastic lymphoma: microarray-based comparative genomic hybridization and gene expression profiling studies with review of literature. \nLeuk Lymphoma. \n2012;\n53(10):1978\u20131987. \ndoi:10.3109\/10428194.2011.618233","DOI":"10.3109\/10428194.2011.618233"},{"key":"2024032423502141800_i1543-2165-148-4-471-b25","doi-asserted-by":"crossref","unstructured":"Khogeer\n              H,\n            \n            \n              Rahman\n              H,\n            \n            \n              Jain\n              N,\n            \n            et al. \n\n          Early T precursor acute lymphoblastic leukaemia\/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. \nBr J Haematol. \n2019;\n186(4):538\u2013548. \ndoi:10.1111\/bjh.15960","DOI":"10.1111\/bjh.15960"},{"key":"2024032423502141800_i1543-2165-148-4-471-b26","doi-asserted-by":"crossref","unstructured":"Phillips\n              AA,\n            \n            \n              Fields\n              PA,\n            \n            \n              Hermine\n              O,\n            \n            et al. \n\n          Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma. \nHaematologica. \n2019;\n104(5):993\u20131003. \ndoi:10.3324\/haematol.2018.205096","DOI":"10.3324\/haematol.2018.205096"},{"key":"2024032423502141800_i1543-2165-148-4-471-b27","doi-asserted-by":"crossref","unstructured":"Muller\n              J,\n            \n            \n              Walter\n              W,\n            \n            \n              Haferlach\n              C,\n            \n            et al. \n\n          How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing. \nLeukemia. \n2023;\n37(1):217\u2013221. \ndoi:10.1038\/s41375-022-01743-6","DOI":"10.1038\/s41375-022-01743-6"},{"key":"2024032423502141800_i1543-2165-148-4-471-b28","doi-asserted-by":"crossref","unstructured":"Alaggio\n              R,\n            \n            \n              Amador\n              C,\n            \n            \n              Anagnostopoulos\n              I,\n            \n            et al. \n\n          The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. \nLeukemia. \n2022;\n36(7):1720\u20131748. \ndoi:10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2024032423502141800_i1543-2165-148-4-471-b29","doi-asserted-by":"crossref","unstructured":"Peirs\n              S,\n            \n            \n              Matthijssens\n              F,\n            \n            \n              Goossens\n              S,\n            \n            et al. \n\n          ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. \nBlood. \n2014;\n124(25):3738\u20133747. \ndoi:10.1182\/blood-2014-05-574566","DOI":"10.1182\/blood-2014-05-574566"},{"key":"2024032423502141800_i1543-2165-148-4-471-b30","doi-asserted-by":"crossref","unstructured":"Bride\n              KL,\n            \n            \n              Vincent\n              TL,\n            \n            \n              Im\n              SY,\n            \n            et al. \n\n          Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. \nBlood. \n2018;\n131(9):995\u2013999. \ndoi:10.1182\/blood-2017-07-794214","DOI":"10.1182\/blood-2017-07-794214"},{"key":"2024032423502141800_i1543-2165-148-4-471-b31","doi-asserted-by":"crossref","unstructured":"Yang\n              K,\n            \n            \n              Xu\n              J,\n            \n            \n              Liu\n              Q,\n            \n            \n              Li\n              J,\n            \n            \n              Xi\n              Y.\n            \n          \n          Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma\/leukemia. \nPathol Res Pract. \n2019;\n215(2):265\u2013271. \ndoi:10.1016\/j.prp.2018.10.021","DOI":"10.1016\/j.prp.2018.10.021"},{"key":"2024032423502141800_i1543-2165-148-4-471-b32","doi-asserted-by":"crossref","unstructured":"Chonghaile\n              TN,\n            \n            \n              Roderick\n              JE,\n            \n            \n              Glenfield\n              C,\n            \n            et al. \n\n          Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. \nCancer Discov. \n2014;\n4(9):1074\u20131087. \ndoi:10.1158\/2159-8290.CD-14-0353","DOI":"10.1158\/2159-8290.CD-14-0353"},{"key":"2024032423502141800_i1543-2165-148-4-471-b33","doi-asserted-by":"crossref","unstructured":"Leclair\n              P,\n            \n            \n              Liu\n              CC,\n            \n            \n              Monajemi\n              M,\n            \n            \n              Reid\n              GS,\n            \n            \n              Sly\n              LM,\n            \n            \n              Lim\n              CJ.\n            \n          \n          CD47-ligation induced cell death in T-acute lymphoblastic leukemia. \nCell Death Dis. \n2018;\n9(5):544. \ndoi:10.1038\/s41419-018-0601-2","DOI":"10.1038\/s41419-018-0601-2"},{"key":"2024032423502141800_i1543-2165-148-4-471-b34","doi-asserted-by":"crossref","unstructured":"Angelova\n              E,\n            \n            \n              Audette\n              C,\n            \n            \n              Kovtun\n              Y,\n            \n            et al. \n\n          CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. \nHaematologica. \n2019;\n104(4):749\u2013755. \ndoi:10.3324\/haematol.2018.205252","DOI":"10.3324\/haematol.2018.205252"},{"key":"2024032423502141800_i1543-2165-148-4-471-b35","doi-asserted-by":"crossref","unstructured":"Hyjek\n              E,\n            \n            \n              Chadburn\n              A,\n            \n            \n              Liu\n              YF,\n            \n            \n              Cesarman\n              E,\n            \n            \n              Knowles\n              DM.\n            \n          \n          BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. \nBlood. \n2001;\n97(1):270\u2013276. \ndoi:10.1182\/blood.v97.1.270","DOI":"10.1182\/blood.V97.1.270"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/148\/4\/471\/3346906\/i1543-2165-148-4-471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/148\/4\/471\/3346906\/i1543-2165-148-4-471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:40:20Z","timestamp":1764790820000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/148\/4\/article-p471.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2022-0482-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}